Editas Medicine (EDIT) News Today $1.31 -0.03 (-2.24%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Evercore ISIDecember 18 at 3:51 AM | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Rating Lowered to Underweight at JPMorgan Chase & Co.December 18 at 2:33 AM | americanbankingnews.comJP Morgan Downgrades Editas Medicine (EDIT)December 17, 2024 | msn.comEditas Medicine price target lowered to $5 from $7 at Evercore ISIDecember 16, 2024 | markets.businessinsider.comCambridge company is laying of 180 people, 65% of its workforceDecember 16, 2024 | msn.comEvercore ISI Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00Evercore ISI decreased their price objective on shares of Editas Medicine from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Monday.December 16, 2024 | marketbeat.comJPMorgan Chase & Co. Downgrades Editas Medicine (NASDAQ:EDIT) to UnderweightJPMorgan Chase & Co. downgraded shares of Editas Medicine from a "neutral" rating to an "underweight" rating in a research note on Monday.December 16, 2024 | marketbeat.comRobert W. Baird Has Lowered Expectations for Editas Medicine (NASDAQ:EDIT) Stock PriceDecember 16, 2024 | americanbankingnews.comRoyal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $4.00December 16, 2024 | americanbankingnews.comEditas Medicine's (EDIT) Neutral Rating Reiterated at Chardan CapitalDecember 16, 2024 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Cut to "Hold" at Truist FinancialDecember 16, 2024 | americanbankingnews.comStifel Downgrades Editas Medicine (EDIT)December 15, 2024 | msn.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $3.00 by Analysts at BarclaysDecember 15, 2024 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Rating Lowered by Stifel NicolausDecember 15, 2024 | americanbankingnews.comChardan Capital Downgrades Editas Medicine (EDIT)December 14, 2024 | msn.comEditas Medicine: Strategic Shift and Uncertainties Prompt Hold RatingDecember 14, 2024 | markets.businessinsider.comEditas Medicine Maintains Hold Rating Amid Strategic Shifts and Financial ChallengesDecember 14, 2024 | markets.businessinsider.comGene-editing pioneer Editas lays off more than half its employeesDecember 14, 2024 | bizjournals.comBrokerages downgrade gene editing company Editas to 'hold', shares slump 23%December 14, 2024 | msn.comRoyal Bank of Canada Issues Pessimistic Forecast for Editas Medicine (NASDAQ:EDIT) Stock PriceRoyal Bank of Canada decreased their price target on shares of Editas Medicine from $5.00 to $4.00 and set a "sector perform" rating on the stock in a report on Friday.December 13, 2024 | marketbeat.comBarclays Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00Barclays reduced their target price on Editas Medicine from $5.00 to $3.00 and set an "equal weight" rating for the company in a research report on Friday.December 13, 2024 | marketbeat.comEditas Medicine: Navigating Uncertainty with a Hold Rating Amid Strategic Shifts and Development ChallengesDecember 13, 2024 | markets.businessinsider.comCautious Outlook for Editas Medicine Amid Strategic Shift and Competitive ChallengesDecember 13, 2024 | markets.businessinsider.comEditas to cut 65% of workforce in strategy shift; shelves lead gene-editing programDecember 13, 2024 | msn.comEditas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "neutral" rating on shares of Editas Medicine in a research report on Friday.December 13, 2024 | marketbeat.comRobert W. Baird Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $8.00Robert W. Baird lowered their target price on shares of Editas Medicine from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Friday.December 13, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Cut to "Hold" at Stifel NicolausStifel Nicolaus lowered Editas Medicine from a "buy" rating to a "hold" rating and cut their price target for the stock from $11.00 to $3.00 in a report on Friday.December 13, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist FinancialTruist Financial downgraded shares of Editas Medicine from a "buy" rating to a "hold" rating in a research report on Friday.December 13, 2024 | marketbeat.comEditas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026December 13, 2024 | benzinga.comEditas to lay off staff after search for sickle cell partner comes up emptyDecember 12, 2024 | finance.yahoo.comEditas to reduce workforce by 65%, announces departure of CMO Baisong MeiDecember 12, 2024 | markets.businessinsider.comEditas to reduce about 65% of its workforce over the next six monthsDecember 12, 2024 | reuters.comEditas Medicine Pivots Gene Editing Strategy, Cutting 65% of WorkforceDecember 12, 2024 | marketwatch.comEditas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two YearsDecember 12, 2024 | globenewswire.comWells Fargo Downgrades Editas Medicine (EDIT)December 12, 2024 | msn.comEditas Medicine downgraded to Equal Weight from Overweight at Wells FargoDecember 11, 2024 | markets.businessinsider.comHold Rating Maintained for Editas Medicine Amid Promising Developments and Safety ConcernsDecember 11, 2024 | markets.businessinsider.comEditas cut to equal weight by Wells Fargo over reni-cel positioningDecember 11, 2024 | msn.com12 Analysts Have This To Say About Editas MedicineDecember 11, 2024 | benzinga.comEditas Medicine Updates RUBY Trial with Promising ResultsDecember 11, 2024 | markets.businessinsider.comWells Fargo & Company Downgrades Editas Medicine (NASDAQ:EDIT) to Equal WeightWells Fargo & Company lowered Editas Medicine from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $7.00 to $4.00 in a research report on Wednesday.December 11, 2024 | marketbeat.comReviewing Arcellx (NASDAQ:ACLX) & Editas Medicine (NASDAQ:EDIT)December 11, 2024 | americanbankingnews.comEditas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | globenewswire.comJacobs Levy Equity Management Inc. Has $1.81 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)Jacobs Levy Equity Management Inc. raised its stake in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 133.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 529,834 shares of the company's stock after aDecember 8, 2024 | marketbeat.comEditas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)December 3, 2024 | seekingalpha.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Hold" from AnalystsEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has earned an average rating of "Hold" from the thirteen analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy ratingDecember 2, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Stock Quotes, Forecast and News SummaryNovember 26, 2024 | benzinga.comBank of America Securities downgrades Editas Medicine (EDIT) to a SellNovember 26, 2024 | markets.businessinsider.comEditas Medicine downgraded to Underperform from Buy at BofANovember 26, 2024 | markets.businessinsider.comEditas Medicine (NASDAQ:EDIT) Downgraded to Underperform Rating by Bank of AmericaBank of America lowered Editas Medicine from a "buy" rating to an "underperform" rating and dropped their price target for the stock from $13.00 to $1.00 in a research note on Monday.November 25, 2024 | marketbeat.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼-0.240.60▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼165▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Anavex Life Sciences News Today AnaptysBio News Today Altimmune News Today Oculis News Today Esperion Therapeutics News Today Ginkgo Bioworks News Today ORIC Pharmaceuticals News Today Phathom Pharmaceuticals News Today Tourmaline Bio News Today Exscientia News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts